BIOSTARPHARM-B：ANNUALRESULTSANNOUNCEMENTFORTHEYEARENDEDDECEMBER312025.pdf

1、Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for thecontents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim anyliability whatsoever for any loss howsoever arising from or in reliance

2、 upon the whole or any part of the contents of thisannouncement.Beijing Biostar Pharmaceuticals Co.,Ltd.北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司(A joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock code:2563)ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 3

3、1,2025The board(the Board)of directors(the Directors)of Beijing Biostar Pharmaceuticals Co.,Ltd.(the Company)hereby announce the audited consolidated results of the Company and itssubsidiaries(collectively,theGroup)fortheyearendedDecember31,2025,alongwithcomparative figures for the year ended Decemb

4、er 31,2024.These annual results have been reviewedby the Audit Committee of the Company and approved by the Board on March 30,2026.In this announcement,we and our refer to the Company,unless otherwise indicated,in which casethey refer to the Group.Certain amounts and percentage figures contained in

5、this announcement havebeen rounded or approximated to one or two decimal places(as applicable).Any differences betweenthe totals and the sum of the amounts shown in any table,chart or elsewhere are due to rounding.Unless otherwise defined,terms used in this announcement have the same meanings as tho

6、se defined inthe Prospectus.FINANCIAL HIGHLIGHTSFor the year endedDecember 31,20252024YOYCHANGERMB000RMB000Revenue33,36471,86653.6%Gross profit30,75762,12150.5%Net profit131,435143,7778.6%Loss for the year attributable to equity shareholders ofthe Company131,435143,7778.6%Loss per share0.360.4112.2%